

Karolinska Development AGM 2020: Information on candidates nominated for election or re-election to the board

Re election

Hans Wigzell

Born 1938. Chairman since 2017. Board member since 2006. Professor Emeritus of Immunology and MD.

Other appointments: Chairman of Rhenman & Partner Asset Management AB. Board member of Sarepta Therapeutics Inc. and RaySearch Laboratories AB. Member of The Royal Swedish Academy of Engineering Sciences and of the Royal Swedish Academy of Sciences. Previous assignments include, among others, the President of Karolinska Institutet's Nobel Committee, and President of Karolinska Institutet and Director General of Smittskyddsinstitutet.

Independent of the company and its executive management, and independent in relation to the company's major shareholders.

Holdings in Karolinska Development: 51,609 shares.

Tse Ping

Born 1952. Vice Chairman and Board member since 2015. Honorary Doctorate, Fil Dr hc.

Other appointments: Founder and CEO of Sino Biopharmaceutical Limited, Chairman and executive director of Hong Kong listed Lamtex Holdings Ltd, Vice Chairman of Charoen Pokphand Group (CP Group), where he has extensive experience of major merger and acquisition activity including Ping An Insurance, CITIC Group, China Mobile, ITOCHU Corporation, and Marko Group. Previous appointments include Member of the Ninth, Tenth, and Eleventh National Committee of the Chinese People's Political Consultative Conference.

Independent of the company and its executive management. Not independent in relation to the company's major shareholders.

Holdings in Karolinska Development: 75,727,285 shares (by related legal person).

Magnus Persson

Born 1960. Board member since 2017. MD PhD Assoc Prof. Educated at Karolinska Institutet.

Other appointments: Chairman of Galecto Biotech AB, Addi Medichal AB, Cantargia AB and Initator Pharma and Board member of Immunicum AB, NeuroVive AB and Oncology Venture AS. Previous assignments CEO Karolinska Institutet Holding AB, Managing Partner The Column Group, Partner HealthCap, Clinical Research Physician Sanofi.

Independent of the company and its executive management, and independent in relation to the company's major shareholders.

No holdings in Karolinska Development.

Theresa Tse

Born 1992. Board Member since 2017. Bachelor Degree of Science in Economics from the Wharton School of University of Pennsylvania.

Other appointments: Executive Director, the Chairlady of the Board and the Chairlady of the Executive Board Committee and the Nomination Committee, respectively, of Sino Biopharmaceutical Ltd (listed in Hong Kong).

Independent of the company and its executive management. Not independent in relation to the company's major shareholders.

Holdings in Karolinska Development: 75,727,285 shares (by related legal person)

New election

Björn Cochlovius

Born 1968. Ph.D., Assoc.Prof.

Other appointments: Chairman of the board of Isogencia Ltd, Founder and General Manager of BC BioMed Consulting GmbH, Partner in Jürg Kurmann Merger and Acquisitions AG, Associate Professor Immunology at Ruprecht-Karls Universität Heidelberg.

Previous assignments: Senior Director Development Asia-Pacific in Abbvie Inc., Director and Head Oncology in Otsuka, Co-founder, Interim-CEO and Chairman of the Board in Ciliatech AG, Director Business Development Oncology in Roche AG, Internal Strategy Consultant in Alpharma AS (now Axellia), Interim CEO in OnTarget Neurology AS, Head R&D in Affitech AS.

Independent of the company and its executive management, and independent in relation to the company's major shareholders.

No holdings in Karolinska Development.